A specialist in clinical trial development, robotic surgery, sentinel lymph node evaluation, and immunotherapy, Dr. Brian Slomovitz is Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center. He is also a Professor of Obstetrics and Gynecology at Florida International University.

Dr. Slomovitz is a member of the Board of Directors at the GOG Foundation and the Uterine Cancer Lead for GOG Partners. He is also the national or global principal investigator on a number of GOG Partners, NCI, and Alliance Foundation clinical trials. He authored more than 100 peer-reviewed articles and lectured extensively. In addition, Dr. Slomovitz has been recognized as a Top Doctor by Castle Connolly Doctor for the past several years.

Dr. Slomovitz graduated from Rutgers University – New Jersey Medical School, and completed his residency at New York Presbyterian – Cornell Medical Center in 2002. At MD Anderson Cancer Center, he completed a fellowship in gynecologic oncology in 2006. He is board certified in both obstetrics and gynecology and gynecologic oncology.

*This physician is employed by Mount Sinai Medical Center

Blog

• Patient Story: Maria Cristina Mitchell
• Patient Overcomes Uterine Cancer through a Non-Chemotherapy Treatment Trial at Mount Sinai Medical Center
• Patient Story: Veronica Vinocur
• New Breakthrough in the treatment of endometrial cancer

Current Trials:

• Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15), Role: Global Principal Investigator, GOG Principal Investigator, Scientific Advisory Board Chair
• ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer, Role: GOG Principal Investigator, Scientific Advisory Board co-Chair
• GOG-3043,”A randomized non-inferiority trial of robotic versus open radical hysterectomy for early-stage cervical cancer”, Steering Committee Member
• AFT-50, EndoMap, “A phase IB/II umbrella study of targeted agents with atezolizumab for patients with recurrent or persistent endometrial cancer”, Role: Principal Investigator, Study Chair, Steering Committee Chair
• GOG 3038, INCMGA00012, “A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO)”, Role: Principal Investigator, Global Study Chair, Governance Committee Chair
• NRG-GY024, “Groningen International Study on Sentinel Nodes in Vulvar Cancer – III, A Prospective Phase II Treatment Trial”, Role: Principal Investigator, GOG Study Chair
• GOG3026, “A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum”, Role: Principal Investigator, Study Chair

Selected Publications:

• Krop IE, Jegede OA, Grilley-Olson JE, Lauring JD, Mitchell EP, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Kono SA, Ford JM, Garcia AA, Sui XD, Siegel RD, Slomovitz BM, Conley BA, Arteaga CL, Harris LN, O’Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precis Oncol. 2022 Feb;6:e2100424. doi: 10.1200/PO.21.00424. PMID: 35138919.
• Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, Millan D, Coleman RL, Moore KN, Banerjee S, Connolly K, Secord AA, O’Malley DM, Dorigo O, Gaillard S, Gabra H, Slomovitz B, Hanjani P, Farley J, Churchman M, Ewing A, Hollis RL, Herrington CS, Huang HQ, Wenzel L, Gourley C. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022 Feb 5;399(10324):541-553. doi: 10.1016/S0140-6736(21)02175-9. PMID: 35123694; PMCID: PMC8819271.
• Slomovitz BM, Filiaci VL, Walker JL, Taub MC, Finkelstein KA, Moroney JW, Fleury AC, Muller CY, Holman LL, Copeland LJ, Miller DS, Coleman RL. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol. 2022 Jan 18:S0090-8258(21)01699-1. doi: 10.1016/j.ygyno.2021.12.031. Epub ahead of print. PMID: 35063278.
• Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. PMID: 35045221 (Study 309–KEYNOTE-775 Investigators-Study Investigator)
• Oonk MHM, Slomovitz B, Baldwin PJW, van Doorn HC, van der Velden J, de Hullu JA, Gaarenstroom KN, Slangen BFM, Vergote I, Brännström M, van Dorst EBL, van Driel WJ, Hermans RH, Nunns D, Widschwendter M, Nugent D, Holland CM, Sharma A, DiSilvestro PA, Mannel R, Boll D, Cibula D, Covens A, Provencher D, Runnebaum IB, Luesley D, Ellis P, Duncan TJ, Tjiong MY, Cruickshank DJ, Kjølhede P, Levenback CF, Bouda J, Kieser KE, Palle C, Spirtos NM, O’Malley DM, Leitao MM, Geller MA, Dhar K, Asher V, Tamussino K, Tobias DH, Borgfeldt C, Lea JS, Bailey J, Lood M, Eyjolfsdottir B, Attard-Montalto S, Tewari KS, Manchanda R, Jensen PT, Persson P, Van Le L, Putter H, de Bock GH, Monk BJ, Creutzberg CL, van der Zee AGJ. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. J Clin Oncol. 2021 Aug 25:JCO2100006. doi: 10.1200/JCO.21.00006.
• Toboni MD, Crane EK, Brown J, Shushkevich A, Chiang S, Slomovitz BM, Levine DA, Dowdy SC, Klopp A, Powell MA, Thaker PH. State of the science: Uterine carcinosarcomas: From pathology to practice. Gynecol Oncol. 2021 May 21:S0090-8258(21)00362-0. doi: 10.1016/j.ygyno.2021.05.003.
• Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, Tewari D, Morris PC, Stevens EE, Bottsford-Miller JN, Tang M, Aaron P, Stanbery L, Horvath S, Wallraven G, Bognar E, Manning L, Nemunaitis J, Shanahan D, Slomovitz BM, Herzog TJ, Monk BJ, Coleman RL. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Oncol. 2020 Dec;21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7. PMID: 33271095.
• Slomovitz B, de Haydu C, Taub M, Coleman RL, Monk BJ. Asbestos and ovarian cancer: examining the historical evidence. Int J Gynecol Cancer. 2021 Jan;31(1):122-128. doi: 10.1136/ijgc-2020-001672. Epub 2020 Oct 9. PMID: 33037108.
• Shushkevich A, Thaker PH, Littell RD, Shah NA, Chiang S, Thornton K, Hensley ML, Slomovitz BM, Holcomb KM, Leitao MM, Toboni MD, Powell MA, Levine DA, Dowdy SC, Klopp A, Brown J. State of the science: Uterine sarcomas: From pathology to practice. Gynecol Oncol. 2020 Aug 21: S0090-8258(20)33764-1.doi:10.1016/j.ygyno. 2020.08.008.
• Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O’Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM. Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 2020 Mar; 156 (3): 715-725. Doi: 10.1016/j.ygyno.2019.12.033.
• Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Machiels JP, Spicer JF, Jones R, Forster MD, Cornez N, Gennigens C, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clin Cancer Res. 2020 Mar 15;26(6):1220-1228. doi: 10.1158/1078-0432.CCR-19-2962.
• González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O’Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.PMID:31562799 (PRIMA study investigator).
• de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K, Ghatta S, Slomovitz BM, Spicer JF, Yachnin J, Ang JE, Mau-Sørensen PM, Forster MD, Collins D, Dean E, Rangwala RA, Lassen U. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(3):383-93. DOI: 10.1016/S1470-2045(18)30859-3.
• Slomovitz BM, Taub MC, Huang M, Levenback C, Coleman R. A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS). Gynecol Oncol Rep. 2019;27:1-4. DOI: 10.1016/j.gore.2018.11.001.
• Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Columbo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O’Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C,  Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA. ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949-61. DOI: 10.1016/S0140-6736(17)32440-6. (member of the ARIEL3 investigators).
• Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dorum A, Tinker AB, du Bois A, Gonzalez-Martin A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016; 375(22):2154-64. (member of ENGOT-OV16/NOVA Investigators). DOI: 10.1056/NEJMoa1611310.
• Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL.  A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33(8):930-6. DOI: 10.1200/JCO.2014.58.3401.
• Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, Sabbatini P, Fu L, Yauch RL, Chang I, Reddy JC. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin Cancer Res. 2012;18(23):6509-18. DOI: 10.1158/1078-0432.CCR-12-1796.
• Slomovitz BM*, Lu, KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, Wolf J. A Phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116(23):5415-9. DOI: 10.1002/cncr.25515.
• Kitchener HC, Trimble EL. Endometrial Cancer Working Group of the Gynecologic Cancer Intergroup (2009) Endometrial Cancer state of the science meeting. Int J Gynecol Cancer. 2009;19(1):134-40. DOI: 10.1111/IGC.0b013e3181995f90. Collaborator.
• Ramirez PT, Schmeler KM, Milam MR, Slomovitz BM, Smith JA, Kavanagh JJ, Deavers M, Levenback C, Coleman RL, Gershenson DM. Efficacy of letrozole in the treatment of recurrent platinum- and taxane- resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol. 2008;110(1):56-9. DOI: 10.1016/j.ygyno.2008.03.014.
• Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol. 2006;108(3):515-20. DOI: 1097/01.AOG.0000228959.30577.13.
• Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Pearson HC, Berenson A, Schmeler K, Ramirez PT, Lu KH ,Bodurka DC. Are women ready for the HPV vaccine? Gynecol Oncol. 2006;103(1): 151-4. PMID: 16551476.
• Schmeler K, Lynch H, Chen L, Munsell M, Soliman PT, Clark M., Daniels M, White K, Boyd-Rogers S, Conrad P, Yang K, Rubin M, Sun CC, Slomovitz BM, Gershenson DM,  Lu KH. Prophylactic surgery for the reduction of gynecologic cancer risk in women with Lynch syndrome (HNPCC). N Engl J Med. 2006;354(3):261-9. PMID: 16421367.
• Ramirez PT, Slomovitz BM, Coleman RL, Soliman PT, Levenback C. Total laparoscopic radical hysterectomy and lymphadenectomy: The M. D. Anderson Cancer Center Experience. Gynecol Oncol. 2006;102(2):252-5. PMID: 16472844.